MK2206

MK2206 · Merck & Co. (assignee varies by trial records)

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for MK2206, covering 2016-02-12 to 2017-09-05. Get the full timeline:

Most recent: Clinical Trial Update: Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer [Phase 2]